Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05317637 · ClinicalTrials.gov registry record
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
A clinical trial of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
- Active
- Registry status
- 18
- Enrollment target
- 3
- Study locations
NCT05317637: Active study of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
NCT05317637 is a study of Osteogenesis Imperfecta that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 18 participants, below the 160-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05317637, a study of Osteogenesis Imperfecta, is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.
Primary Outcome
FEV1/FVC greater than or equal to 80%, which is obtained from PFT
Conditions Studied
Study Locations (3)
California
- University of California Los Angeles - Los Angeles
Maryland
- Kennedy Krieger Institute / Hugo W. Moser Research Institute - Baltimore
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2027-09-01 |
What the registry record for NCT05317637 still lists
NCT05317637 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 160-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 0 interventions.
NCT05317637 reports a single indexed study location in California, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT05317637 about?
NCT05317637 is a clinical study titled "Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708". Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 ...
What is the current status of trial NCT05317637?
This trial is currently active not recruiting. The enrollment target is 18 participants. The study started on 2022-08-01. Estimated completion is 2027-09-01.
What conditions does trial NCT05317637 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta.
Who is sponsoring clinical trial NCT05317637?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05317637 being conducted?
This trial has 3 study locations across California, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteogenesis Imperfecta
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05317637's enrollment target sits among peer trials
18 13th of 13 higher than 1 of 13 other Osteogenesis Imperfecta trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteogenesis Imperfecta trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
RECRUITING · Phase 3
-
Effects of Bisphosphonates on OI-Related Hearing Loss
RECRUITING · Phase 4
-
BBD Longitudinal Study of Osteogenesis Imperfecta
RECRUITING
-
Setrusumab vs Placebo for Osteogenesis Imperfecta
ACTIVE NOT RECRUITING · Phase 2
-
Urinary Biomarkers of OI Pathobiology
ACTIVE NOT RECRUITING
-
Clear Aligners for the Treatment of Dental Malocclusion in OI
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI